{
    "organizations": [],
    "uuid": "443da84aea797703eb4fb61e8488fbcf4b9f85d1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-us-fda-grants-fast-track-designati/brief-u-s-fda-grants-fast-track-designation-for-krystal-biotechs-kb103-idUSASC0A3JW",
    "ord_in_thread": 0,
    "title": "BRIEF-U.S. FDA Grants Fast Track Designation For Krystal Biotech’S Kb103",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 24 (Reuters) - Krystal Biotech Inc:\n* U.S. FDA GRANTS FAST TRACK DESIGNATION FOR KRYSTAL BIOTECH’S KB103 FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-24T20:33:00.000+03:00",
    "crawled": "2018-05-25T16:10:11.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "krystal",
        "biotech",
        "inc",
        "fda",
        "grant",
        "fast",
        "track",
        "designation",
        "krystal",
        "biotech",
        "kb103",
        "treatment",
        "dystrophic",
        "epidermolysis",
        "bullosa",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}